Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852

Lung Cancer Research Foundation (merged with Free to Breathe)

participant Login

Lung Cancer Info

Targeted Therapy

Share |

Targeted therapies, medications for lung cancerOver the past decade, scientists have made many discoveries about what makes cancer cells multiply out of control. They have discovered that one way cancer cells are different from normal cells is that they often have abnormalities or mutations in their DNA; in response, scientists are developing drugs that specifically “target” cancer cells with these mutations to stop or limit the growth and spread of cancer. These therapies are also called “molecularly targeted therapies/drugs” or “precision medicines,” because they precisely target the mutation that is causing the patient’s cancer. 

Mutations that can be targeted with currently available treatments include:

  • Epidermal Growth Factor Receptor (EGFR) mutations
    • T790M mutation
  • Anaplastic Lymphoma Kinase (ALK) gene rearrangement
  • ROS1 gene rearrangement
  • BRAF V600E mutation

Patients with the EGFR mutation may take drugs like erlotinib (Tarceva®) or afatinib (Gilotrif®), or gefitinib (Iressa®). Osimertinib (Tagrisso®) is available for patients whose tumors have the T790M mutation. Patients with ALK mutations may take ceritinib (Zykadia®), crizotinib (Xalkori®), alectinib (Alecensa®), or brigatinib (Alunbrig™). Crizotinib is also used to treat patients who have ROS1-positive NSCLC. Patients whose tumors have the BRAF V600 mutation may be treated with the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®).

Other targeted therapy drugs, like bevacizumab (Avastin®) and ramucirumab (Cyramza®), can stop angiogenesis, (a process where the tumor makes new blood vessels). Blocking the ability of a tumor to make blood vessels can prevent it from getting the oxygen and nutrients it needs to grow. These drugs are sometimes given along with chemotherapy

Because these treatments work best for people whose tumors have specific gene changes or mutations, testing the tumor tissue for these mutations is very important. These tests can be called molecular, biomarker, genetic or mutation testing.

Many more drugs are being tested in clinical trials to determine if they can target other types of mutations, and even more drugs are in other stages of development. Molecular tumor testing is often required to check whether you are eligible for targeted therapies and clinical trials.

< Back to Treatment Options

This information is not designed to be a substitute for medical advice provided by your treatment team.
Last updated 8/2017

©2018 Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.